APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pomalidomide

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pomalidomide Market Outlook and Growth Opportunities 2026

23 December 2025199 pages

Choose your research edition.

Industry ResearchPomalidomide Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Pomalidomide Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Pomalidomide Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pomalidomide Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Pomalidomide Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pomalidomide market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pomalidomide is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pomalidomide market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pomalidomide market include Celgene, Chia Tai-Tianqing, Cipla, Dr Reddy's Laboratories, Hanson Pharm, Indiabulls pharmaceutical, Intas Pharmaceuticals, Meidakang Huakang Pharmaceutical and Natco Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pomalidomide market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pomalidomide and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pomalidomide sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pomalidomide market size, projected growth trends, production technologies, key applications, and end-use industries.

Pomalidomide Segment by Company

Celgene

Chia Tai-Tianqing

Cipla

Dr Reddy's Laboratories

Hanson Pharm

Indiabulls pharmaceutical

Intas Pharmaceuticals

Meidakang Huakang Pharmaceutical

Natco Pharma

SL PHARM

Glenmark Pharmaceuticals

Qilu Pharmaceutical

Shandong Kongfu Pharmaceutical

Pomalidomide Segment by Type

1mg Tables

2mg Tables

4mg Tables

Pomalidomide Segment by Application

Clinic

Hospital

Drug Center

Others

Pomalidomide Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pomalidomide status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pomalidomide market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pomalidomide significant trends, drivers, influence factors in global and regions.

6. To analyze Pomalidomide competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pomalidomide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pomalidomide and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pomalidomide.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pomalidomide market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pomalidomide industry.

Chapter 3: Detailed analysis of Pomalidomide manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pomalidomide in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pomalidomide in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pomalidomide Industry Trends Table 2. Pomalidomide Industry Drivers Table 3. Pomalidomide Industry Opportunities and Challenges Table 4. Pomalidomide Industry Restraints Table 5. Global Pomalidomide Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pomalidomide Revenue Share by Company (2021-2026) Table 7. Global Pomalidomide Sales Volume by Company (k pcs) & (2021-2026) Table 8. Global Pomalidomide Sales Volume Share by Company (2021-2026) Table 9. Global Pomalidomide Average Price (US$/pcs) of Company (2021-2026) Table 10. Global Pomalidomide Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pomalidomide Key Company Manufacturing Base & Headquarters Table 12. Global Pomalidomide Company, Product Type & Application Table 13. Global Pomalidomide Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pomalidomide by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 1mg Tables Table 18. Significant Companies of 2mg Tables Table 19. Significant Companies of 4mg Tables Table 20. Global Pomalidomide Sales Volume by Type 2021 VS 2025 VS 2032 (k pcs) Table 21. Global Pomalidomide Sales Volume by Type (2021-2026) & (k pcs) Table 22. Global Pomalidomide Sales Volume by Type (2027-2032) & (k pcs) Table 23. Global Pomalidomide Sales Volume Share by Type (2021-2026) Table 24. Global Pomalidomide Sales Volume Share by Type (2027-2032) Table 25. Global Pomalidomide Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Pomalidomide Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Pomalidomide Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Pomalidomide Sales Value Share by Type (2021-2026) Table 29. Global Pomalidomide Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Clinic Table 31. Significant Companies of Hospital Table 32. Significant Companies of Drug Center Table 33. Significant Companies of Others Table 34. Global Pomalidomide Sales Volume by Application 2021 VS 2025 VS 2032 (k pcs) Table 35. Global Pomalidomide Sales Volume by Application (2021-2026) & (k pcs) Table 36. Global Pomalidomide Sales Volume by Application (2027-2032) & (k pcs) Table 37. Global Pomalidomide Sales Volume Share by Application (2021-2026) Table 38. Global Pomalidomide Sales Volume Share by Application (2027-2032) Table 39. Global Pomalidomide Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Pomalidomide Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Pomalidomide Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Pomalidomide Sales Value Share by Application (2021-2026) Table 43. Global Pomalidomide Sales Value Share by Application (2027-2032) Table 44. Global Pomalidomide Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 45. Global Pomalidomide Sales by Region (2021-2026) & (k pcs) Table 46. Global Pomalidomide Sales Market Share by Region (2021-2026) Table 47. Global Pomalidomide Sales by Region (2027-2032) & (k pcs) Table 48. Global Pomalidomide Sales Market Share by Region (2027-2032) Table 49. Global Pomalidomide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Pomalidomide Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Pomalidomide Sales Value Share by Region (2021-2026) Table 52. Global Pomalidomide Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Pomalidomide Sales Value Share by Region (2027-2032) Table 54. Global Pomalidomide Market Average Price (US$/pcs) by Region (2021-2026) Table 55. Global Pomalidomide Market Average Price (US$/pcs) by Region (2027-2032) Table 56. Global Pomalidomide Sales by Country: 2021 VS 2025 VS 2032 (k pcs) Table 57. Global Pomalidomide Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Pomalidomide Sales by Country (2021-2026) & (k pcs) Table 59. Global Pomalidomide Sales Market Share by Country (2021-2026) Table 60. Global Pomalidomide Sales by Country (2027-2032) & (k pcs) Table 61. Global Pomalidomide Sales Market Share by Country (2027-2032) Table 62. Global Pomalidomide Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Pomalidomide Sales Value Market Share by Country (2021-2026) Table 64. Global Pomalidomide Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Pomalidomide Sales Value Market Share by Country (2027-2032) Table 66. Celgene Company Information Table 67. Celgene Business Overview Table 68. Celgene Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 69. Celgene Pomalidomide Product Portfolio Table 70. Celgene Recent Development Table 71. Chia Tai-Tianqing Company Information Table 72. Chia Tai-Tianqing Business Overview Table 73. Chia Tai-Tianqing Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 74. Chia Tai-Tianqing Pomalidomide Product Portfolio Table 75. Chia Tai-Tianqing Recent Development Table 76. Cipla Company Information Table 77. Cipla Business Overview Table 78. Cipla Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 79. Cipla Pomalidomide Product Portfolio Table 80. Cipla Recent Development Table 81. Dr Reddy's Laboratories Company Information Table 82. Dr Reddy's Laboratories Business Overview Table 83. Dr Reddy's Laboratories Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 84. Dr Reddy's Laboratories Pomalidomide Product Portfolio Table 85. Dr Reddy's Laboratories Recent Development Table 86. Hanson Pharm Company Information Table 87. Hanson Pharm Business Overview Table 88. Hanson Pharm Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 89. Hanson Pharm Pomalidomide Product Portfolio Table 90. Hanson Pharm Recent Development Table 91. Indiabulls pharmaceutical Company Information Table 92. Indiabulls pharmaceutical Business Overview Table 93. Indiabulls pharmaceutical Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 94. Indiabulls pharmaceutical Pomalidomide Product Portfolio Table 95. Indiabulls pharmaceutical Recent Development Table 96. Intas Pharmaceuticals Company Information Table 97. Intas Pharmaceuticals Business Overview Table 98. Intas Pharmaceuticals Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 99. Intas Pharmaceuticals Pomalidomide Product Portfolio Table 100. Intas Pharmaceuticals Recent Development Table 101. Meidakang Huakang Pharmaceutical Company Information Table 102. Meidakang Huakang Pharmaceutical Business Overview Table 103. Meidakang Huakang Pharmaceutical Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 104. Meidakang Huakang Pharmaceutical Pomalidomide Product Portfolio Table 105. Meidakang Huakang Pharmaceutical Recent Development Table 106. Natco Pharma Company Information Table 107. Natco Pharma Business Overview Table 108. Natco Pharma Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 109. Natco Pharma Pomalidomide Product Portfolio Table 110. Natco Pharma Recent Development Table 111. SL PHARM Company Information Table 112. SL PHARM Business Overview Table 113. SL PHARM Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 114. SL PHARM Pomalidomide Product Portfolio Table 115. SL PHARM Recent Development Table 116. Glenmark Pharmaceuticals Company Information Table 117. Glenmark Pharmaceuticals Business Overview Table 118. Glenmark Pharmaceuticals Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 119. Glenmark Pharmaceuticals Pomalidomide Product Portfolio Table 120. Glenmark Pharmaceuticals Recent Development Table 121. Qilu Pharmaceutical Company Information Table 122. Qilu Pharmaceutical Business Overview Table 123. Qilu Pharmaceutical Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 124. Qilu Pharmaceutical Pomalidomide Product Portfolio Table 125. Qilu Pharmaceutical Recent Development Table 126. Shandong Kongfu Pharmaceutical Company Information Table 127. Shandong Kongfu Pharmaceutical Business Overview Table 128. Shandong Kongfu Pharmaceutical Pomalidomide Sales (k pcs), Value (US$ Million), Price (US$/pcs) and Gross Margin (2021-2026) Table 129. Shandong Kongfu Pharmaceutical Pomalidomide Product Portfolio Table 130. Shandong Kongfu Pharmaceutical Recent Development Table 131. Key Raw Materials Table 132. Raw Materials Key Suppliers Table 133. Pomalidomide Distributors List Table 134. Pomalidomide Customers List Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Pomalidomide Product Image Figure 2. Global Pomalidomide Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pomalidomide Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pomalidomide Sales (2021-2032) & (k pcs) Figure 5. Global Pomalidomide Sales Average Price (US$/pcs) & (2021-2032) Figure 6. Global Pomalidomide Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 1mg Tables Image Figure 10. 2mg Tables Image Figure 11. 4mg Tables Image Figure 12. Global Pomalidomide Sales Volume by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 13. Global Pomalidomide Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Pomalidomide Sales Volume Share by Type (2021-2032) Figure 15. Global Pomalidomide Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Pomalidomide Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Pomalidomide Sales Value Share by Type (2021-2032) Figure 18. Clinic Image Figure 19. Hospital Image Figure 20. Drug Center Image Figure 21. Others Image Figure 22. Global Pomalidomide Sales Volume by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 23. Global Pomalidomide Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Pomalidomide Sales Volume Share by Application (2021-2032) Figure 25. Global Pomalidomide Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Pomalidomide Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Pomalidomide Sales Value Share by Application (2021-2032) Figure 28. Global Pomalidomide Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Figure 29. Global Pomalidomide Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Pomalidomide Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Pomalidomide Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Pomalidomide Sales Value (2021-2032) & (US$ Million) Figure 33. North America Pomalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Pomalidomide Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Pomalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Pomalidomide Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Pomalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Pomalidomide Sales Value (2021-2032) & (US$ Million) Figure 39. South America Pomalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Pomalidomide Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Pomalidomide Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Pomalidomide Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Pomalidomide Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Pomalidomide Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Pomalidomide Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Pomalidomide Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • 1mg Tables
  • 2mg Tables
  • 4mg Tables
Applications
  • Clinic
  • Hospital
  • Drug Center
  • Others
Companies covered
  • Celgene
  • Chia Tai-Tianqing
  • Cipla
  • Dr Reddy's Laboratories
  • Hanson Pharm
  • Indiabulls pharmaceutical
  • Intas Pharmaceuticals
  • Meidakang Huakang Pharmaceutical
  • Natco Pharma
  • SL PHARM
  • Glenmark Pharmaceuticals
  • Qilu Pharmaceutical
  • Shandong Kongfu Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pomalidomide Sales Value (2021-2032)
  4. 1.2.2 Global Pomalidomide Sales Volume (2021-2032)
  5. 1.2.3 Global Pomalidomide Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pomalidomide Market Dynamics
  1. 2.1 Pomalidomide Industry Trends
  2. 2.2 Pomalidomide Industry Drivers
  3. 2.3 Pomalidomide Industry Opportunities and Challenges
  4. 2.4 Pomalidomide Industry Restraints
3 Pomalidomide Market by Company
  1. 3.1 Global Pomalidomide Company Revenue Ranking in 2025
  2. 3.2 Global Pomalidomide Revenue by Company (2021-2026)
  3. 3.3 Global Pomalidomide Sales Volume by Company (2021-2026)
  4. 3.4 Global Pomalidomide Average Price by Company (2021-2026)
  5. 3.5 Global Pomalidomide Company Ranking (2024-2026)
  6. 3.6 Global Pomalidomide Company Manufacturing Base and Headquarters
  7. 3.7 Global Pomalidomide Company Product Type and Application
  8. 3.8 Global Pomalidomide Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pomalidomide Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pomalidomide Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pomalidomide Market by Type
  1. 4.1 Pomalidomide Type Introduction
  2. 4.1.1 1mg Tables
  3. 4.1.2 2mg Tables
  4. 4.1.3 4mg Tables
  5. 4.2 Global Pomalidomide Sales Volume by Type
  6. 4.2.1 Global Pomalidomide Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Pomalidomide Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Pomalidomide Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Pomalidomide Sales Value by Type
  10. 4.3.1 Global Pomalidomide Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Pomalidomide Sales Value by Type (2021-2032)
  12. 4.3.3 Global Pomalidomide Sales Value Share by Type (2021-2032)
5 Pomalidomide Market by Application
  1. 5.1 Pomalidomide Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Drug Center
  5. 5.1.4 Others
  6. 5.2 Global Pomalidomide Sales Volume by Application
  7. 5.2.1 Global Pomalidomide Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Pomalidomide Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Pomalidomide Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Pomalidomide Sales Value by Application
  11. 5.3.1 Global Pomalidomide Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Pomalidomide Sales Value by Application (2021-2032)
  13. 5.3.3 Global Pomalidomide Sales Value Share by Application (2021-2032)
6 Pomalidomide Regional Sales and Value Analysis
  1. 6.1 Global Pomalidomide Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pomalidomide Sales by Region (2021-2032)
  3. 6.2.1 Global Pomalidomide Sales by Region: 2021-2026
  4. 6.2.2 Global Pomalidomide Sales by Region (2027-2032)
  5. 6.3 Global Pomalidomide Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pomalidomide Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pomalidomide Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pomalidomide Sales Value by Region (2027-2032)
  9. 6.5 Global Pomalidomide Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pomalidomide Sales Value (2021-2032)
  12. 6.6.2 North America Pomalidomide Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pomalidomide Sales Value (2021-2032)
  15. 6.7.2 Europe Pomalidomide Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pomalidomide Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pomalidomide Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pomalidomide Sales Value (2021-2032)
  21. 6.9.2 South America Pomalidomide Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pomalidomide Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pomalidomide Sales Value Share by Country, 2025 VS 2032
7 Pomalidomide Country-level Sales and Value Analysis
  1. 7.1 Global Pomalidomide Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pomalidomide Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pomalidomide Sales by Country (2021-2032)
  4. 7.3.1 Global Pomalidomide Sales by Country (2021-2026)
  5. 7.3.2 Global Pomalidomide Sales by Country (2027-2032)
  6. 7.4 Global Pomalidomide Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pomalidomide Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pomalidomide Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pomalidomide Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pomalidomide Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pomalidomide Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pomalidomide Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pomalidomide Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pomalidomide Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pomalidomide Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pomalidomide Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pomalidomide Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pomalidomide Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pomalidomide Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pomalidomide Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pomalidomide Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pomalidomide Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pomalidomide Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pomalidomide Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pomalidomide Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pomalidomide Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pomalidomide Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pomalidomide Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pomalidomide Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pomalidomide Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pomalidomide Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pomalidomide Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pomalidomide Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pomalidomide Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pomalidomide Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pomalidomide Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pomalidomide Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pomalidomide Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pomalidomide Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pomalidomide Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pomalidomide Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pomalidomide Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pomalidomide Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pomalidomide Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pomalidomide Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pomalidomide Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pomalidomide Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pomalidomide Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pomalidomide Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pomalidomide Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pomalidomide Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pomalidomide Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pomalidomide Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pomalidomide Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pomalidomide Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pomalidomide Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pomalidomide Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pomalidomide Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pomalidomide Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pomalidomide Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pomalidomide Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pomalidomide Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pomalidomide Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pomalidomide Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pomalidomide Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pomalidomide Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pomalidomide Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pomalidomide Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pomalidomide Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pomalidomide Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pomalidomide Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pomalidomide Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pomalidomide Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pomalidomide Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pomalidomide Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pomalidomide Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pomalidomide Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pomalidomide Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pomalidomide Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pomalidomide Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pomalidomide Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pomalidomide Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pomalidomide Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pomalidomide Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pomalidomide Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pomalidomide Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pomalidomide Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pomalidomide Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pomalidomide Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pomalidomide Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pomalidomide Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pomalidomide Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Celgene
  2. 8.1.1 Celgene Company Information
  3. 8.1.2 Celgene Business Overview
  4. 8.1.3 Celgene Pomalidomide Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Celgene Pomalidomide Product Portfolio
  6. 8.1.5 Celgene Recent Developments
  7. 8.2 Chia Tai-Tianqing
  8. 8.2.1 Chia Tai-Tianqing Company Information
  9. 8.2.2 Chia Tai-Tianqing Business Overview
  10. 8.2.3 Chia Tai-Tianqing Pomalidomide Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Chia Tai-Tianqing Pomalidomide Product Portfolio
  12. 8.2.5 Chia Tai-Tianqing Recent Developments
  13. 8.3 Cipla
  14. 8.3.1 Cipla Company Information
  15. 8.3.2 Cipla Business Overview
  16. 8.3.3 Cipla Pomalidomide Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cipla Pomalidomide Product Portfolio
  18. 8.3.5 Cipla Recent Developments
  19. 8.4 Dr Reddy's Laboratories
  20. 8.4.1 Dr Reddy's Laboratories Company Information
  21. 8.4.2 Dr Reddy's Laboratories Business Overview
  22. 8.4.3 Dr Reddy's Laboratories Pomalidomide Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Dr Reddy's Laboratories Pomalidomide Product Portfolio
  24. 8.4.5 Dr Reddy's Laboratories Recent Developments
  25. 8.5 Hanson Pharm
  26. 8.5.1 Hanson Pharm Company Information
  27. 8.5.2 Hanson Pharm Business Overview
  28. 8.5.3 Hanson Pharm Pomalidomide Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Hanson Pharm Pomalidomide Product Portfolio
  30. 8.5.5 Hanson Pharm Recent Developments
  31. 8.6 Indiabulls pharmaceutical
  32. 8.6.1 Indiabulls pharmaceutical Company Information
  33. 8.6.2 Indiabulls pharmaceutical Business Overview
  34. 8.6.3 Indiabulls pharmaceutical Pomalidomide Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Indiabulls pharmaceutical Pomalidomide Product Portfolio
  36. 8.6.5 Indiabulls pharmaceutical Recent Developments
  37. 8.7 Intas Pharmaceuticals
  38. 8.7.1 Intas Pharmaceuticals Company Information
  39. 8.7.2 Intas Pharmaceuticals Business Overview
  40. 8.7.3 Intas Pharmaceuticals Pomalidomide Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Intas Pharmaceuticals Pomalidomide Product Portfolio
  42. 8.7.5 Intas Pharmaceuticals Recent Developments
  43. 8.8 Meidakang Huakang Pharmaceutical
  44. 8.8.1 Meidakang Huakang Pharmaceutical Company Information
  45. 8.8.2 Meidakang Huakang Pharmaceutical Business Overview
  46. 8.8.3 Meidakang Huakang Pharmaceutical Pomalidomide Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Meidakang Huakang Pharmaceutical Pomalidomide Product Portfolio
  48. 8.8.5 Meidakang Huakang Pharmaceutical Recent Developments
  49. 8.9 Natco Pharma
  50. 8.9.1 Natco Pharma Company Information
  51. 8.9.2 Natco Pharma Business Overview
  52. 8.9.3 Natco Pharma Pomalidomide Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Natco Pharma Pomalidomide Product Portfolio
  54. 8.9.5 Natco Pharma Recent Developments
  55. 8.10 SL PHARM
  56. 8.10.1 SL PHARM Company Information
  57. 8.10.2 SL PHARM Business Overview
  58. 8.10.3 SL PHARM Pomalidomide Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 SL PHARM Pomalidomide Product Portfolio
  60. 8.10.5 SL PHARM Recent Developments
  61. 8.11 Glenmark Pharmaceuticals
  62. 8.11.1 Glenmark Pharmaceuticals Company Information
  63. 8.11.2 Glenmark Pharmaceuticals Business Overview
  64. 8.11.3 Glenmark Pharmaceuticals Pomalidomide Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Glenmark Pharmaceuticals Pomalidomide Product Portfolio
  66. 8.11.5 Glenmark Pharmaceuticals Recent Developments
  67. 8.12 Qilu Pharmaceutical
  68. 8.12.1 Qilu Pharmaceutical Company Information
  69. 8.12.2 Qilu Pharmaceutical Business Overview
  70. 8.12.3 Qilu Pharmaceutical Pomalidomide Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Qilu Pharmaceutical Pomalidomide Product Portfolio
  72. 8.12.5 Qilu Pharmaceutical Recent Developments
  73. 8.13 Shandong Kongfu Pharmaceutical
  74. 8.13.1 Shandong Kongfu Pharmaceutical Company Information
  75. 8.13.2 Shandong Kongfu Pharmaceutical Business Overview
  76. 8.13.3 Shandong Kongfu Pharmaceutical Pomalidomide Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Shandong Kongfu Pharmaceutical Pomalidomide Product Portfolio
  78. 8.13.5 Shandong Kongfu Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pomalidomide Value Chain Analysis
  2. 9.1.1 Pomalidomide Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pomalidomide Sales Mode & Process
  6. 9.2 Pomalidomide Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pomalidomide Distributors
  9. 9.2.3 Pomalidomide Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst